GBT Announces New Employment Inducement Grants
December 09, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2021, the compensation committee of GBT’s board...
GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease Program
December 02, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.; The ASH Research Collaborative
WASHINGTON and SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of...
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th...
GBT Announces Participation in Upcoming Investor Conferences
November 12, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel...
GBT Announces New Employment Inducement Grants
November 08, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on November 1, 2021, the compensation committee of GBT’s board...
GBT Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target...
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
November 04, 2021 09:05 ET
|
Global Blood Therapeutics, Inc.
Accepted Abstracts Include Real-World Experience with Oxbryta® (voxelotor) and Phase 1 Data on GBT021601 and Inclacumab SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood...
GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor)
November 01, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honors Oxbryta as the Best Biotechnology Product for 2021 Oxbryta is the first and only approved therapy...
GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4
October 28, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
Company to also host R&D Day on Thursday, November 11 in New York City and via video webcast SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT)...
GBT Announces New Employment Inducement Grants
October 07, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2021, the compensation committee of GBT’s board...